股价表现与盈利预期 - 过去一个月，TransUnion (TRU) 股价上涨4.1%，表现优于行业0.7%的涨幅 [1] - 公司2025年第四季度盈利预计同比增长5.2% [1] - 2025年和2026年盈利预计分别增长8.7%和13.1% [1] - 2025年和2026年营收预计分别增长8.5%和7.7% [1] 增长驱动因素 - 营收增长由快速增长的大数据和分析市场驱动，且美国经济和信贷环境稳定 [2] - 海量数据生成、快速数据处理技术及分析的进步推动了公司扩张 [2] - 美国市场适度的GDP增长、低失业率、稳定的拖欠率、较低的利率以及可控的通胀共同助力公司表现 [2] 技术与产品创新 - 通过OneTru平台进行技术现代化，该平台将原本分离的信贷风险、营销和欺诈缓解数据与分析资产整合到一个统一的分层环境中，加速了信贷与非信贷产品的创新 [3] - TrueIQ分析平台加速了数据模型构建周期，实现了更快的数据处理速度，并为美国信贷客户提供无缝访问 [3] - 2025年，TrueIQ分析平台已在加拿大、英国和印度推出，并计划未来向这些市场输出其他基于OneTru的解决方案 [4] - 近期在Snowflake市场上推出TrueIQ数据丰富服务，扩大了数据丰富的市场机会，并彰显了公司对客户的承诺 [4] 业务与市场拓展 - 2017年收购的消费者报告机构Factor Trust表现良好，今年在消费信贷业务中获得了多项成功 [4] - 公司在一个高度竞争的市场中运营，竞争对手包括Equifax、Experian、FICO和LexisNexis [6] 财务状况 - 截至2025年第三季度末，公司的流动比率为2.01，高于行业平均的0.98，表明公司能够轻松偿付短期债务 [5]

For investors seeking momentum, abrdn Physical Silver Shares ETF (SIVR) is probably on the radar. The fund just hit a 52-week high and is up 172.12% from its 52-week low price of $26.19/share.But are there more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:SIVR in FocusThis ETF is designed to track the spot price of silver bullion. The product charges 30 bps in annual fees (See: All Precious Metals ETFs).Why ...

Key Points If you're thinking about claiming Social Security next year, you need to understand how your claim will impact your retirement income. Your claiming age will affect your monthly and lifetime benefits. The data is clear on the best age to claim, and if you aren't reaching that age next year, you should carefully consider your options. The $23,760 Social Security bonus most retirees completely overlook › Deciding when to claim Social Security can impact your finances throughout your ent ...

Jim Cramer has built a strong reputation in the industry. He's the Mad Money host who carefully picks growth stocks that have the potential to survive market ups and downs. When it comes to dividend stocks, he thinks there are many stocks with a high yield, but as yields soar, it can become dangerous since the company may not be in a position to cover the cost of the dividend. Loading stock data... However, he thinks these dividend stocks are different, which is why he recommends them. Jim Cramer has picked ...

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply on Monday.Mereo BioPharma and its partner Ultragenyx revealed results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). Osteogenesis Imperfecta (OI) includes a group of genetic disorders impacting bone metabolism. The collagen mutations in OI can result in increased bone brittleness, which contributes to a high rate of fractures.Ultragenyx Pharmaceutical shares dipped 42% to $19.84 on Monday.H ...

Soft Bank announcing a deal in the data center space today. Christina Partzene has the details in today's tech check segment. Christina Sarah, like you mentioned, they're buying a data center firm called Digital Bridge for $4 billion at 16 bucks a share all cash.The stock you can see jumping almost 10 10% today on the news. Digital Bridge manages about $ 108 billion worth of data center assets. And this deal is basically SoftBank's founder Masayoshi Sun saying quote I need an AI infrastructure and I need it ...

DENVER--(BUSINESS WIRE)--Modivcare Inc. (the "Company†or "Modivcare†) (OTCMKTS: MODVQ), a technology-enabled healthcare services company providing a platform of integrated supportive care solutions focused on improving health outcomes, today announced the completion of its financial restructuring process and emergence from Chapter 11 protection. Modivcare achieved the objectives it set for this process, including meaningfully reducing funded debt by $1.1 billion—more than 85% of prior funded debt—and succ ...

Over the past three years, Nvidia (NASDAQ:NVDA ) stock has climbed by over 1,200% to dizzyingly high levels. ...

Five years after sharing her journey, Amoye Henry sees progress for Black women founders in Canada.Amoye Henry is an investor, ecosystem catalyst and global consultant backing visionaries and challenging the status quo. She is the co-founder of Pitch Better, a startup that trains entrepreneurs to build and scale sustainable small businesses.In 2020, I wrote an article for BetaKit titled “The horrifying truth of being a Black woman founder in Canada.” It revealed a painful truth: across thousands of Canadia ...

公司战略调整 - 公司决定终止acasunlimab的进一步临床开发[1] - 此决定是基于公司战略，旨在聚焦其后期产品管线中能创造最大价值的机会[1] - 决策也源于对不断变化的竞争格局进行的全面评估[1] 资源重新分配 - 尽管acasunlimab迄今的临床数据令人鼓舞，但公司将把资源集中在具有最高潜在影响力的项目上[2] - 重点推进的后期开发项目包括Epkinly (epcoritamab)、petosemtamab以及rinatabart sesutecan (Rina-S)[2] 项目背景与财务影响 - 该决定不影响公司2025年全年的财务指引[3] - 2024年8月，因BioNTech SE选择不参与acasunlimab项目的进一步开发，公司已承担该药物的全部开发和潜在商业化责任[3] - 根据公司网站信息，acasunlimab曾涉及四项癌症临床试验，包括一项针对非小细胞肺癌的三期研究、两项针对黑色素瘤和非小细胞肺癌的二期试验，以及一项针对实体瘤的一期试验[4] 市场反应与分析师观点 - 分析师此前预测acasunlimab的峰值销售额约为3亿美元，并认为其对公司的峰值收入机会贡献微小[5] - 分析师指出，公司三项主要资产的合并峰值销售潜力可达80亿美元，因此重申“跑赢大盘”评级，认为公司有显著上行潜力[5] - 消息发布后，公司股价下跌2.05%至32.73美元[6]